Skip to search formSkip to main contentSkip to account menu

OPC 41061

Known as: OPC-41061 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tolvaptan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Dehydration effects of a V2 antagonist on endolymphatic hydrops in guinea pigs
2008
2008
Double-Blind, Placebo-Controlled, Multicenter Trial of a Vasopressin V2-Receptor Antagonist in Patients with Schizophrenia and Hyponatremia
2008
2008
Therapy for polycystic kidney disease? It's water, stupid!
Water, which is preeminent among all biomolecular compounds, creates more complexities than implied by simple H2O. Humans are… 
Review
2006
Review
2006
Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
Review
2005
Review
2005
Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure.
Highly Cited
2003
Highly Cited
2003
Vasopressin V 2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure Results From a Double-Blind , Randomized Trial
Background—In this study, we evaluated the effects of tolvaptan (OPC-41061), a novel, oral, nonpeptide vasopressin V2-receptor… 
Review
2002
Review
2002
Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
Highly Cited
2000
Highly Cited
2000
Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats.
This study was conducted to characterize the diuretic effect of OPC-41061, a nonpeptide vasopressin V(2)-receptor antagonist, and… 
Highly Cited
1999
Highly Cited
1999
7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.
Highly Cited
1998
Highly Cited
1998
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
The pharmacological profile and the acute and chronic aquaretic effects of OPC-41061, a novel nonpeptide human arginine… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)